Mesothelioma: open trials in China

• NCT05579366

  Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  Trial Treatment · Phase 1/2 · Genmab

  Cancer Hospital, Chinese Academy of Medical Sciences, Beijing · Jilin Cancer Hospital, Changchun · Hunan Cancer Hospital - Phase 1, Changsha · Hunan Cancer Hospital - Thoracic Medicine Dept II, Changsha · Obstetrics & Gynecology Hospital of Fudan University, Chengdu · Chongqing University Cancer Hospital, Chongqing · Fujian Cancer Hospital, Fujian · Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong · Zhejiang Cancer Hospital, Hangzhou · Second Affiliated Hospital of Zhengzhou University, Henan · Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei · Jiangxi maternal and child health hospital, Nanchang · Shanghai East Hospital, Shanghai · Fudan University Shanghai Cancer Center- Phase 1, Shanghai · Fudan University Shanghai Cancer Center - Gynecologic Oncology, Shanghai · Sichuan Cancer Hospital, Shanghai · Second Hospital of Shanxi Medical University, Shanxi · Shanxi Cancer Hospital, Shanxi · Liaoning Cancer Hospital & Institute, Shengyang · Tianjin Cancer Hospital, Tianjin

  Registry updated 2026-11-04

• NCT07885319

  Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma

  Trial Treatment · Phase 1/2 · Ruijin Hospital

  West China Hospital of Sichuan University, Chengdu · Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai · Shanghai Chest Hospital, Shanghai

  Registry updated 2026-11-02

• NCT07893340

  First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal Mesothelioma

  Trial Treatment · Phase 2 · Fudan University

  Fudan University Shanghai Cancer Center, Shanghai

  Registry updated 2026-10-23

• NCT06566079

  Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

  Trial Treatment · Phase 1/2 · InSilico Medicine Hong Kong Limited

  Cancer Hospital, Chinese Academy of Medical Sciences, Beijing · Sun Yat-sen University Cancer Center, Guangzhou · Shanghai Pulmonary Hospital, Shanghai · Henan Cancer Hospital, Zhengzhou

  Registry updated 2026-09-16

• NCT06535607

  Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

  Trial Treatment · Phase 2 · AstraZeneca

  Anyang · Beijing · Bengbu · Changchun · Changsha · Chengdu · Chongqing · Dongguan · Fuzhou · Guangzhou · Hangzhou · Harbin · Hefei · Jining · Kunming · Nanchang · Nanjing · Nanning · Shandong · Shanghai · Shenyang · Tianjin · Wuhan · Wuhou District · Zhengzhou

  Registry updated 2026-09-11

• NCT03917043

  APG-2449 in Patients With Advanced Solid Tumors

  Trial Treatment · Phase 1 · Ascentage Pharma Group Inc.

  Beijing Cancer Hospital, Beijing · Hunan Provincial Oncology Hospital, Changsha · Fujian Medical University Union Hospital, Fuzhou · Fujian Cancer Hospital, Fuzhou · The First Affiliated Hospital, Sun Yat-sen University, Guangzhou · Sun Yat-sen University Cancer Center, Guangzhou · Zhejiang Provincial Oncology Hospital, Hangzhou · Union Hospital medical college Huazhong University of Science and Technology, Wuhan · Henan Provincial Oncology Hospital, Zhengzhou

  Registry updated 2026-07-23

• NCT07330271

  PTC-Guided Therapy for Peritoneal Mesothelioma

  Trial Treatment · Beijing Tsinghua Chang Gung Hospital

  Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital, Beijing

  Registry updated 2026-06-15

• NCT07514793

  Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma

  Trial Treatment · Phase 2 · Fudan University

  Fudan University Cancer hospital, Shanghai

  Registry updated 2026-04-07

• NCT07510815

  Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma

  Trial Treatment · Phase 1/2 · Beijing Biotech

  Peking University Shenzhen Hospital, Shenzhen

  Registry updated 2026-04-06

• NCT07282873

  Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors

  Trial Treatment · Phase 1/2 · TYK Medicines, Inc

  Shanghai Chest Hospital, Shanghai

  Registry updated 2025-12-22

• NCT05188859

  First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

  Trial Treatment · Phase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  Cancer Hospital, Chinese Academy of Medical Sciences, Beijing · Shanxi Provincial Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan

  Registry updated 2025-05-31

• NCT06875076

  Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma

  Trial Treatment · Phase 2 · The First Hospital of Jilin University

  Cancer center, First Hospital of Jilin University, Changchun

  Registry updated 2025-03-13

• NCT06726564

  A Study of MT027 in Patients with Pleural Malignant Tumors

  Trial Treatment · Phase 1 · Suzhou Maximum Bio-tech Co., Ltd.

  Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

  Registry updated 2024-12-10

• NCT06543069

  Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

  Trial Treatment · Phase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

  Registry updated 2024-08-07

• NCT06196294

  GPC3/Mesothelin-CAR-γδT Cells Against Cancers

  Trial Treatment · Phase 1 · Second Affiliated Hospital of Guangzhou Medical University

  The second Affiliated Hospital of Guangzhou Medical University, Guangzhou

  Registry updated 2024-06-26

All Mesothelioma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error